Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M14,989Revenue $M4,464Net Margin (%)7.5Z-Score4.4
Enterprise Value $M15,943EPS $2.0Operating Margin %10.5F-Score7
P/E(ttm))45.0Cash Flow Per Share $4.7Pre-tax Margin (%)8.7Higher ROA y-yY
Price/Book4.510-y EBITDA Growth Rate %-5.1Quick Ratio1.4Cash flow > EarningsY
Price/Sales3.45-y EBITDA Growth Rate %-10.3Current Ratio2.3Lower Leverage y-yY
Price/Cash Flow6.8y-y EBITDA Growth Rate %221ROA % (ttm)5.2Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)10.4Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M171ROI % (ttm)-1.9Gross Margin Increase y-yY

Gurus Latest Trades with HSP

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
HSPJoel Greenblatt 2014-12-31 Sold Out -0.16%$48.12 - $62.84
($56.62)
$ 87.6135%Sold Out0
HSPJohn Rogers 2014-12-31 Reduce-0.08%$48.12 - $62.84
($56.54)
$ 87.6135%Reduce -5.02%2,311,309
HSPVanguard Health Care Fund 2014-12-31 Reduce-0.05%$48.12 - $62.84
($56.54)
$ 87.6135%Reduce -4.87%7,966,970
HSPMario Gabelli 2014-12-31 Add0.03%$48.12 - $62.84
($56.51)
$ 87.6135%Add 38.25%352,370
HSPJohn Rogers 2014-09-30 Reduce-0.45%$49.59 - $56.21
($53.12)
$ 87.6139%Reduce -22.28%2,433,369
HSPJoel Greenblatt 2014-09-30 Buy 0.16%$49.59 - $56.21
($53.12)
$ 87.6139%New holding313,242
HSPMario Gabelli 2014-09-30 Add0.01%$49.59 - $56.21
($53.12)
$ 87.6139%Add 24.71%254,870
HSPJohn Rogers 2014-06-30 Reduce-0.53%$42.14 - $52.41
($47.4)
$ 87.6146%Reduce -24.15%3,130,809
HSPMario Gabelli 2014-06-30 Add0.01%$42.14 - $52.41
($47.4)
$ 87.6146%Add 32.91%204,370
HSPBrian Rogers 2014-03-31 Sold Out -0.37%$40.89 - $45
($42.84)
$ 87.6151%Sold Out0
HSPJohn Rogers 2014-03-31 Reduce-0.28%$40.89 - $45
($42.84)
$ 87.6151%Reduce -11.62%4,127,850
HSPVanguard Health Care Fund 2014-03-31 Add0.18%$40.89 - $45
($42.83)
$ 87.6151%Add 22.69%8,375,170
HSPMario Gabelli 2014-03-31 Add0.01%$40.89 - $45
($42.84)
$ 87.6151%Add 30.68%153,770
HSPJohn Rogers 2013-12-31 Add0.12%$38.53 - $42.19
($40.25)
$ 87.6154%Add 5.28%4,670,630
HSPRichard Pzena 2013-09-30 Sold Out -0.27%$38.45 - $42.03
($39.88)
$ 87.6154%Sold Out0
HSPJohn Rogers 2013-09-30 Reduce-0.23%$38.45 - $42.03
($39.88)
$ 87.6154%Reduce -7.79%4,436,305
HSPJohn Rogers 2013-06-30 Add0.34%$30.57 - $38.31
($33.81)
$ 87.6161%Add 12.97%4,811,105
HSPBrian Rogers 2013-06-30 Add0.24%$30.57 - $38.31
($33.81)
$ 87.6161%Add 135.30%2,750,000
HSPMichael Price 2013-03-31 Add0.65%$28.96 - $35.99
($32.42)
$ 87.6163%Add 61.62%400,000
HSPVanguard Health Care Fund 2013-03-31 Add0.62%$28.96 - $35.99
($32.42)
$ 87.6163%Add 242.15%6,826,070
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

HSP is held by these investors:


News about HSP:

Articles On GuruFocus.com
John Rogers' Ariel Fund Q1 2015 Commentary Apr 16 2015 
Weekly 52-Week Highs Highlight: SIAL, GIS, TJX, HSP Mar 30 2015 
Hospira’s Q4 Earnings Were Bright, Though Acquisition Is In The Cards Feb 19 2015 
Analysts Weigh in on Pfizer Following Acquisition Announcement of Hospira Feb 06 2015 
Feeling Good With This Med Company Jan 20 2015 
Weekly Insider Sells Highlight: REGN, HSP, TYC, AAPL Nov 30 2014 
Weekly CFO Sells Highlight: Hospira Inc, Rockwood Holdings Inc, Mylan Inc. Nov 30 2014 
Jeff Auxier Second Quarter Shareholder Letter Aug 08 2014 
Brian Rogers' T. Rowe Price Equity Income Fund Semi-Annual Report 2013 Dec 02 2013 
Ariel Capital's John Rogers Trims Sotheby’s, DeVry, Hospira, IPG, Others Nov 18 2013 


More From Other Websites
DaVita HealthCare (DVA), Hospira (HSP), Berkshire Hathaway (BRK.A) Lead LMR Partners’ Portfolio... Apr 24 2015
Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on... Apr 24 2015
Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on... Apr 24 2015
Lazard revenues ride dealmaking wave Apr 23 2015
Coatue Management Starts New Position in Actavis Apr 22 2015
Merck Gets Bullied in Norway With Remicade Price War Apr 22 2015
Pfizer: Juicy Dividend, Strong Pipeline, Big Gains Apr 21 2015
Four Tips for Buying the Dip Apr 18 2015
James Pallotta’s Raptor Capital Hits Homerun with Hospira, Inc. (HSP) Apr 17 2015
Need to change the laws on corporate tax: Pfizer CEO Apr 16 2015
Banks see talent flee amid healthcare M&A boom Apr 14 2015
Will Pharmaceutical Sales Drive J&J (JNJ) Earnings Again? - Analyst Blog Apr 13 2015
Hope for Greater Access for Patients to Biosimilar Medicines Apr 13 2015
Hope for Greater Access for Patients to Biosimilar Medicines Apr 13 2015
The Medicines Co. Posts Disappointing Preliminary Results - Analyst Blog Apr 10 2015
Hospira Slammed with Another Warning Letter by the FDA - Analyst Blog Apr 08 2015
Hospira hit with further FDA scrutiny after $17 billion Pfizer deal Apr 08 2015
Hospira to Announce First-Quarter 2015 Results on April 28, 2015 Apr 07 2015
Hospira to Announce First-Quarter 2015 Results on April 28, 2015 Apr 07 2015
Boston Scientific Boosts Endoscopy Business, Buys Xlumena - Analyst Blog Apr 07 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK